BMC Infectious Diseases最新文献

筛选
英文 中文
Assessment of the diagnostic significance of pentraxin-3 in conjunction with procalcitonin (PCT) and C-reactive protein (CRP) for neonatal sepsis.
IF 3.4 3区 医学
BMC Infectious Diseases Pub Date : 2025-03-24 DOI: 10.1186/s12879-025-10821-w
Yan Jin, Shuang Guo, Yanfeng Xiao, Chunyan Yin
{"title":"Assessment of the diagnostic significance of pentraxin-3 in conjunction with procalcitonin (PCT) and C-reactive protein (CRP) for neonatal sepsis.","authors":"Yan Jin, Shuang Guo, Yanfeng Xiao, Chunyan Yin","doi":"10.1186/s12879-025-10821-w","DOIUrl":"10.1186/s12879-025-10821-w","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to compare serum levels of pentraxin-3 (PTX-3) in neonates with sepsis against those without sepsis and to assess the diagnostic value of PTX-3 in relation to conventional inflammatory markers.</p><p><strong>Methods: </strong>Between June and December 2020, a total of 109 neonates aged 1 to 21 days, with birth weights ranging from 1795 g to 4200 g, and who met the diagnostic criteria outlined in the \"Expert Consensus on the Diagnosis and Treatment of Neonatal Sepsis\" (2019) were examined in this prospective study, including 35 with sepsis, 36 with localized infections, and 38 without any infections. Neonates with congenital malformations, intrauterine viral infections, prior antibiotic treatment or without parental consent were excluded from the study. Blood samples were collected and analyzed for routine blood parameters, liver and kidney function metrics, levels of C-reactive protein (CRP), procalcitonin (PCT), lactic acid, and PTX-3.</p><p><strong>Results: </strong>The incidence of premature rupture of membranes was significantly lower in the sepsis and localized infection groups compared to the non-infected group (22.86%, 11.11%, and 2.63%; P < 0.05). White blood cell (WBC) counts were significantly elevated in both the sepsis and localized infection groups when compared to the non-infected group (P < 0.05). Notable differences were also found in lactate dehydrogenase (LDH) and calcium (Ca) levels (P < 0.05). Serum levels of CRP, PCT, and PTX-3 were significantly higher in the sepsis group (P < 0.05). Additionally, PTX-3 levels demonstrated a strong correlation with both CRP and PCT (P < 0.01). PTX-3, PCT, and platelet distribution width (PDW) emerged as independent risk factors for neonatal infection, while WBC, platelet count (PLT), CRP, PTX-3, PDW, and pH were identified as independent risk factors for sepsis (P < 0.05). The combination of PTX-3, CRP, PCT, and WBC exhibited the highest diagnostic efficiency for neonatal infection (AUC = 0.954, sensitivity 97.4%, specificity 83.1%; P < 0.01). For sepsis, the combined markers also demonstrated the best diagnostic performance (AUC = 0.855, sensitivity 83.3%, specificity 80.0%; P < 0.01).</p><p><strong>Conclusion: </strong>PTX-3 shows promise as a biomarker for neonatal sepsis, and when combined with WBC, CRP, and PCT, it significantly enhances both diagnostic sensitivity and specificity.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"401"},"PeriodicalIF":3.4,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modulation of RAAS receptors and miRNAs in COVID-19: implications for disease severity, immune response, and potential therapeutic targets.
IF 3.4 3区 医学
BMC Infectious Diseases Pub Date : 2025-03-24 DOI: 10.1186/s12879-025-10803-y
Thais Freitas Barreto Fernandes, Jose Henrique Pilotto, Priscila Alves Cezar, Fernanda Heloise Côrtes, Mariza G Morgado, Carmem Beatriz W Giacoia-Gripp, Nathalia Beatriz Ramos De Sá, Andressa Da Silva Cazote, Agatha Freixinho Neves, Marcel De Souza Borges Quintana, Maria Pia Diniz Ribeiro, Sandra Wagner Cardoso, Valdiléa G Veloso, Beatriz Grinsztejn, Dalziza Victalina De Almeida
{"title":"Modulation of RAAS receptors and miRNAs in COVID-19: implications for disease severity, immune response, and potential therapeutic targets.","authors":"Thais Freitas Barreto Fernandes, Jose Henrique Pilotto, Priscila Alves Cezar, Fernanda Heloise Côrtes, Mariza G Morgado, Carmem Beatriz W Giacoia-Gripp, Nathalia Beatriz Ramos De Sá, Andressa Da Silva Cazote, Agatha Freixinho Neves, Marcel De Souza Borges Quintana, Maria Pia Diniz Ribeiro, Sandra Wagner Cardoso, Valdiléa G Veloso, Beatriz Grinsztejn, Dalziza Victalina De Almeida","doi":"10.1186/s12879-025-10803-y","DOIUrl":"10.1186/s12879-025-10803-y","url":null,"abstract":"<p><p>The SARS-CoV-2 spike protein interacts with ACE2, a key receptor within the renin-angiotensin-aldosterone system (RAAS), which plays a critical role in maintaining vascular homeostasis, regulating blood pressure, and modulating inflammation. An observational study analyzed the gene expression profiles of RAAS receptors and associated miRNAs in 88 hospitalized COVID-19 patients and 20 healthy controls, comparing the acute and post-acute phases to assess their impact on disease severity and recovery. Our findings revealed an association between reduced MAS1 expression in both advanced age (P = 0.03) and the need for oxygen supplementation (P = 0.04). Additionally, reduced ACE expression was associated with worse mortality outcomes (P = 0.01). Notably, ACE2 and TMPRSS2 expression was significantly decreased (P < 0.0001) in individuals requiring oxygen supplementation and in those with diabetes mellitus during both the acute and post-COVID-19 phases, further highlighting the impact of these conditions on RAAS. The miRNA analysis revealed significant downregulation of miR-200c (P = 0.005), miR-let-7 (P = 0.01), and miR-122 (P = 0.03) in acute-phase COVID-19 patients. This dysregulation contributes to the inflammatory response and highlights the interaction between viral entry and immune regulation. These results underscore the significance of the ACE2/Ang-(1-7)/MAS1 axis in inflammation regulation and suggest that targeting this pathway may have therapeutic potential. Our study provides valuable insights into the molecular mechanisms of COVID-19 pathogenesis and identifies the modulation of RAAS receptors and miRNAs as promising biomarkers for disease severity and potential therapeutic interventions. CLINICAL TRIAL: Not applicable.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"399"},"PeriodicalIF":3.4,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Empirical versus pre-emptive antifungal therapies for invasive fungal infections in critically ill patients. 治疗重症患者侵袭性真菌感染的经验性抗真菌疗法与先发制人的抗真菌疗法。
IF 3.4 3区 医学
BMC Infectious Diseases Pub Date : 2025-03-22 DOI: 10.1186/s12879-025-10816-7
Hong Tham Pham, Ronald L Castelino, Tyree H Kiser, Kim-Huong Truong-Nguyen, Minh-Hoang Tran
{"title":"Empirical versus pre-emptive antifungal therapies for invasive fungal infections in critically ill patients.","authors":"Hong Tham Pham, Ronald L Castelino, Tyree H Kiser, Kim-Huong Truong-Nguyen, Minh-Hoang Tran","doi":"10.1186/s12879-025-10816-7","DOIUrl":"10.1186/s12879-025-10816-7","url":null,"abstract":"<p><strong>Background: </strong>The initiation strategy of antifungal therapy (AT) is among the most discussed practices for patients vulnerable to invasive fungal infections (IFI). In low-resource countries, there are also no appropriate consensus or guidelines for this issue. Given this clinical gap, we aimed to investigate the use of empirical and pre-emptive therapy in an Asian intensive care setting.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study (timeframe 2019-2020) on critically ill adults receiving systemic antifungals for ≥ 3 days. The exposure was empirical or pre-emptive therapy of systemic antifungals. The primary outcome was IFI-related mortality (in percentage, including in-hospital death or discharge/transfer with death prognosis). The secondary outcomes included overall rationale of AT (in percentage) and length of AT (LoAT, in days). We used logistic and linear regression to investigate the outcomes and reported the estimates with the 95% confidence interval (95% CI).</p><p><strong>Results: </strong>During a median follow-up of 27 days, among 157 included patients (median age 68, 48.4% being female), we recorded 77 deaths (49.0% [95% CI 41.0-57.1%]) that were related to IFI (60 [51.7%] in the empirical group; 17 [41.5%] in the pre-emptive group; adjusted odds ratio of IFI-related mortality 1.86 [95% CI 0.74 to 4.63; p = 0.184]). The overall rationale of AT was at 45.2% (95% CI 37.2-53.4%; 41.4% [95% CI 32.3-50.9%] in the empirical group; 56.1% [95% CI 40.0-71.5%] in the pre-emptive group; adjusted odds ratio of receiving rational AT: 0.75 [95% CI 0.31 to 1.87]). The median LoAT was 8 days (IQR 6-14; 8 days [IQR 6-13.3] in the empirical group; 9 days [IQR 6-14] in the pre-emptive group; adjusted mean difference - 1.1 days [95% CI -3.2 to 1.0]).</p><p><strong>Conclusion: </strong>Among critically ill patients on systemic antifungals for ≥ 3 days, the proportion of IFI-related mortality was high. The overall rationale of AT was at a low level, with the median LoAT lower than the generally recommended duration of at least 14 days. There were no significant differences in IFI-related mortality, overall rationale of AT, and LoAT between those receiving empirical and pre-emptive therapy.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"395"},"PeriodicalIF":3.4,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical utility of the FilmArray® meningitis/encephalitis panel in children with suspected central nervous system infection in a low-resource setting - a prospective study in Southwestern Uganda. FilmArray® 脑膜炎/脑炎样本在资源匮乏地区疑似中枢神经系统感染儿童中的临床应用--乌干达西南部的一项前瞻性研究。
IF 3.4 3区 医学
BMC Infectious Diseases Pub Date : 2025-03-22 DOI: 10.1186/s12879-025-10732-w
Reza Rasti, Elias Kumbakumba, Deborah Nanjebe, Phuthumani Mlotshwa, Milly Nassejje, John Mzee, Stephen Businge, Gilbert Akankwasa, Dan Nyehangane, Jesper Gantelius, Yap Boum, Andreas Mårtensson, Juliet Mwanga-Amumpaire, Tobias Alfvén, Giulia Gaudenzi
{"title":"Clinical utility of the FilmArray® meningitis/encephalitis panel in children with suspected central nervous system infection in a low-resource setting - a prospective study in Southwestern Uganda.","authors":"Reza Rasti, Elias Kumbakumba, Deborah Nanjebe, Phuthumani Mlotshwa, Milly Nassejje, John Mzee, Stephen Businge, Gilbert Akankwasa, Dan Nyehangane, Jesper Gantelius, Yap Boum, Andreas Mårtensson, Juliet Mwanga-Amumpaire, Tobias Alfvén, Giulia Gaudenzi","doi":"10.1186/s12879-025-10732-w","DOIUrl":"10.1186/s12879-025-10732-w","url":null,"abstract":"<p><strong>Background: </strong>In low-resource settings, limited laboratory capacity adds to the burden of central nervous system (CNS) infections in children and spurs overuse of antibiotics. The commercially available BioFire® FilmArray® Meningitis/Encephalitis Panel (FA-ME) with its capability to simultaneously detect 14 pathogens in cerebrospinal fluid (CSF), could potentially narrow such a diagnostic gap.</p><p><strong>Methods: </strong>In Mbarara, Uganda, we compared clinical utility (clinical turnaround time [cTAT], microbial yield, and influence on patient outcome and antibiotic exposure) of FA-ME with bacterial culture, in children 0-12 years with suspected CNS infection.</p><p><strong>Results: </strong>Of 212 enrolled children, CSF was sampled from 194. All samples underwent bacterial culture, of which 193 also underwent FA-ME analyses. FA-ME analyses prospectively influenced care for 169 of the 193 patients, and they constituted an 'Index group'. The remaining 43/212 patients constituted a 'Reference group'. Of all 194 CSF-sampled patients, 87% (168) had received antibiotics before lumbar puncture. Median cTAT for FA-ME was 4.2 h, vs. two days for culture. Bacterial yield was 12% (24/193) and 1.5% (3/194) for FA-ME and culture, respectively. FA-ME viral yield was 12% (23/193). Fatality rate was 14% in the Index group vs. 19% in the Reference group (P = 0.20). From clinician receival of FA-ME results, median antibiotic exposure was 6 days for bacteria-negative vs. 13 days for bacteria-positive patients (P = 0.03). Median hospitalization duration was 7 vs. 12 days for FA-ME negative and positive patients, respectively (P < 0.01).</p><p><strong>Conclusions: </strong>In this setting, clinical FA-ME utility was found in a higher and faster microbial yield and shortened hospitalization and antibiotic exposure of patients without CSF pathology. More epidemiologically customized pathogen panels may increase FA-ME utility locally, although its use in similar settings would require major cost reductions.</p><p><strong>Trial registration: </strong>The trial was registered with clinicaltrials.gov (NCT03900091) in March 2019, and its protocol was published in November 2020.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"396"},"PeriodicalIF":3.4,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11930002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological characteristics and spatiotemporal distribution of hepatitis C in southeast coastal areas of China from 2015 to 2022.
IF 3.4 3区 医学
BMC Infectious Diseases Pub Date : 2025-03-21 DOI: 10.1186/s12879-025-10778-w
Wei Liu, Qiaoling Lian, Zongqing Li, Xiaoli Lu, Shaobin Wu, Mingya Zhang, Yunjiao Pan, Yixiang Lin, Jianfeng Xie
{"title":"Epidemiological characteristics and spatiotemporal distribution of hepatitis C in southeast coastal areas of China from 2015 to 2022.","authors":"Wei Liu, Qiaoling Lian, Zongqing Li, Xiaoli Lu, Shaobin Wu, Mingya Zhang, Yunjiao Pan, Yixiang Lin, Jianfeng Xie","doi":"10.1186/s12879-025-10778-w","DOIUrl":"10.1186/s12879-025-10778-w","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study was to analyze the epidemiological characteristics and spatial-temporal distribution characteristics of hepatitis C in Fujian Province, China, from 2015 to 2022, and to provide reference for the risk identification, early warning and prevention and control measures of hepatitis C in Fujian Province.</p><p><strong>Methods: </strong>The incidence data of hepatitis C in Fujian Province from 2015 to 2022 were collected from the China Information System for Disease Control and Prevention. Descriptive epidemiology method and JRP 4.9.1.0 software were used to analyze the epidemiological characteristics of hepatitis C in Fujian Province from 2015 to 2022. ArcGIS 10.8 software was used for spatial autocorrelation analysis of the reported incidence of hepatitis C, and SaTScan 10.1.3 software was used for spatio-temporal scanning analysis.</p><p><strong>Results: </strong>A total of 18,712 cases of hepatitis C were reported in Fujian Province from 2015 to 2022, and the annual reported incidence showed a decreasing trend (AAPC =-10.4, P < 0.001). Males were more affected, accounting for 55.7% (n = 10,429) of all reported hepatitis C cases compared to 44.3% (n = 8,283) for females. Among all age groups, the number of cases in people aged 40-60 was the largest, accounting for 43.2%. Autocorrelation analysis showed that the reported cases of hepatitis C from 2015 to 2022 were clustered, and the global Moran´s I values were all greater than 0 (P < 0.001). Local autocorrelation analysis showed that the high-high concentration area of hepatitis C incidence was relatively fixed and concentrated in the Putian city. The spatial and temporal scanning analysis detected one largest possible agglomeration area, Xiuyu District of Putian city, and two type II agglomeration areas were mainly distributed in economically developed cities along the coastal line.</p><p><strong>Conclusion: </strong>The reported incidence of hepatitis C in Fujian province showed a downward trend from 2015 to 2022, and there were obvious epidemic characteristics and spatial-temporal clustering of hepatitis C. Attention should be paid not only to the key population of 40-60 years old males in rural areas and the key gathering areas in Putian City, but also to the incidence of hepatitis C in southeast coastal areas.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"394"},"PeriodicalIF":3.4,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Standard versus double dosing of beta-lactam antibiotics in critically ill patients with sepsis: The BULLSEYE study protocol for a multicenter randomized controlled trial. 脓毒症重症患者使用β-内酰胺类抗生素的标准剂量与双重剂量:BULLSEYE 多中心随机对照试验研究方案。
IF 3.4 3区 医学
BMC Infectious Diseases Pub Date : 2025-03-21 DOI: 10.1186/s12879-025-10747-3
M M B Horstink, D R Geel, C A den Uil, P E Deetman, H Endeman, A Abdulla, T M Bosch, W J R Rietdijk, F W Thielen, J J Haringman, P van Vliet, T A Rijpstra, C Bethlehem, A Beishuizen, A E Muller, B C P Koch
{"title":"Standard versus double dosing of beta-lactam antibiotics in critically ill patients with sepsis: The BULLSEYE study protocol for a multicenter randomized controlled trial.","authors":"M M B Horstink, D R Geel, C A den Uil, P E Deetman, H Endeman, A Abdulla, T M Bosch, W J R Rietdijk, F W Thielen, J J Haringman, P van Vliet, T A Rijpstra, C Bethlehem, A Beishuizen, A E Muller, B C P Koch","doi":"10.1186/s12879-025-10747-3","DOIUrl":"10.1186/s12879-025-10747-3","url":null,"abstract":"<p><strong>Background: </strong>Sepsis and septic shock are significant global healthcare challenges with high mortality rates. Effective management requires timely and adequate antimicrobial therapy. Beta-lactam antibiotics, commonly used in patients with sepsis, are crucial for treating these infections. However, standard dosing often leads to insufficient plasma levels due to dynamic physiological changes in critically ill patients. Previous randomized controlled trials highlighted the need for timely dose adjustments to improve clinical outcomes. This is the study protocol for the BULLSEYE trial in which we aim to optimize antibiotic treatment during the initial 48 h of sepsis by comparing standard to double dosing of beta-lactam antibiotics.</p><p><strong>Methods: </strong>This open-label, multicenter, randomized controlled trial will compare standard to double dosing of beta-lactam antibiotics (cefuroxime, ceftazidime, ceftriaxone, cefotaxime, amoxicillin, amoxicillin/clavulanic acid, flucloxacillin, meropenem, and piperacillin/clavulanic acid) in critically ill patients with septic shock. Participants will be randomized into two arms: the control arm receiving standard care, and the intervention arm receiving double antibiotic doses for 48 h, irrespective of renal function. Following this period, all patients will receive standard doses as per local protocol. The primary outcome is all cause 28-day mortality, with secondary outcomes including 90-day, 365-day, hospital and ICU mortality, hospital and ICU length of stay, SOFA scores, time to shock reversal, microbiological eradication, clinical cure, pharmacodynamic target attainment, safety, quality of life, and medical consumption.</p><p><strong>Discussion: </strong>The BULLSEYE trial aims to improve sepsis treatment in critically ill patients. Despite anticipated recruitment challenges, its large sample size ensures robust comparability. This pivotal trial could significantly impact sepsis treatment, leading to better clinical outcomes.</p><p><strong>Trial registration: </strong>EU_CT 2024-512950-13-00. Protocol version 2.3, protocol date 09-12-2024. Prospectively registered on 09-01-2025 at Clinicaltrails.gov nr. NCT06766461.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"392"},"PeriodicalIF":3.4,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case of septic shock caused by drug-resistant Edwardsiella tarda and literature review.
IF 3.4 3区 医学
BMC Infectious Diseases Pub Date : 2025-03-21 DOI: 10.1186/s12879-025-10789-7
Yan Zhou, De Ren, Yin Li, Shuiqing Gui
{"title":"A case of septic shock caused by drug-resistant Edwardsiella tarda and literature review.","authors":"Yan Zhou, De Ren, Yin Li, Shuiqing Gui","doi":"10.1186/s12879-025-10789-7","DOIUrl":"10.1186/s12879-025-10789-7","url":null,"abstract":"<p><strong>Background: </strong>Edwardsiella tarda (E. tarda) causes highly mortality, which is rare in septic patients. We herein reported a case of septic shock caused by drug-resistant E. tarda.</p><p><strong>Case presentation: </strong>We herein describe a 32-year-old female with septic shock who had the medical history of abortion 1 month ago and \"systemic lupus erythematosus and rheumatoid arthritis\" presented abdominal pain, diarrhea, and dyspnea as the primary symptoms and rapidly deteriorated to MODS following breakfast (undercooked fish porridge) in the ICU. Sepsis surviving bundle was initiated by collecting pathogen culture (sputum, urine and blood samples), empirically broad-spectrum antibiotics administration (Meropenem), along with fluid resuscitation, vasopressor use. E. tarda was confirmed both in blood culture and mNGS (metagenomics next generation sequencing). Thus, the antibiotics were switched to piperacillin-tazobactam according to the susceptibility test that was susceptible to piperacillin-tazobactam and resistant to ampicillin, quinolones and gentamicin. The patient finally recovered and discharged after 18 days of ICU treatment.</p><p><strong>Conclusions: </strong>Empiric antibiotics should be selected with piperacillin-tazobactam and amikacin, and avoid ampicillin, quinolones and gentamicin for suspecting E. tarda infection in southern China. Bacteremia complicated with septic shock caused by E. tarda requires intensive care to improve survival rates.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"393"},"PeriodicalIF":3.4,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between the extent of intrapulmonary spread on chest CT and false-negative results of T-SPOT.TB in pulmonary tuberculosis: a retrospective study.
IF 3.4 3区 医学
BMC Infectious Diseases Pub Date : 2025-03-20 DOI: 10.1186/s12879-025-10777-x
Ryo Sato, Naoki Takasaka, Yusuke Hosaka, Taiki Fukuda, Kyota Shinfuku, Makiko Takatsuka, Tsukasa Hasegawa, Masami Yamada, Yumie Yamanaka, Kai Ryu, Takeo Ishikawa, Jun Araya
{"title":"Association between the extent of intrapulmonary spread on chest CT and false-negative results of T-SPOT.TB in pulmonary tuberculosis: a retrospective study.","authors":"Ryo Sato, Naoki Takasaka, Yusuke Hosaka, Taiki Fukuda, Kyota Shinfuku, Makiko Takatsuka, Tsukasa Hasegawa, Masami Yamada, Yumie Yamanaka, Kai Ryu, Takeo Ishikawa, Jun Araya","doi":"10.1186/s12879-025-10777-x","DOIUrl":"10.1186/s12879-025-10777-x","url":null,"abstract":"<p><strong>Background: </strong>The T-SPOT.TB assay is widely used for the adjunctive diagnosis of tuberculosis (TB). However, clinicians often encounter false-negative T-SPOT.TB results. The extent of TB spread may influence host immune functions, which can influence the results of the T-SPOT.TB test. However, few previous reports have investigated the association between radiologic pulmonary tuberculosis (PTB) severity and T-SPOT.TB test results.</p><p><strong>Methods: </strong>We retrospectively investigated patients with culture-confirmed pulmonary TB (PTB) at the Jikei University Daisan Hospital between September 2016 and December 2021. We aimed to clarify the association of PTB severity, according to computed tomography (CT), with the false-negative results of the T-SPOT.TB test.</p><p><strong>Results: </strong>Among 193 patients with PTB, 43 (22.3%) had false-negative T-SPOT.TB results. High rates of false-negative results were noted for 7/18 (38.9%) patients with PTB spread in two lung segments (mild PTB) and 16/39 (41.0%) patients with PTB spread in 19 lung segments (severe PTB). Multivariate logistic regression analysis showed that mild or severe PTB (odds ratio [OR]: 3.23; 95% confidence interval [CI]: 1.46-7.13; P = 0.004) and lymphopenia (OR: 3.33; 95% CI: 1.20-9.26; P = 0.02) were statistically significant risk factors for false-negative results.</p><p><strong>Conclusions: </strong>Mild or severe intrapulmonary lesions on chest CT might be associated with the false-negative results of the T-SPOT.TB assay. Additionally, estimating the intrapulmonary spread of PTB using chest CT could serve as a useful supplementary tool in diagnosing patients with PTB who receive false-negative results on the T-SPOT.TB test.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"391"},"PeriodicalIF":3.4,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lateral-flow device for the diagnosis of invasive aspergillosis: a systematic review and diagnostic meta-analysis.
IF 3.4 3区 医学
BMC Infectious Diseases Pub Date : 2025-03-20 DOI: 10.1186/s12879-025-10769-x
Yuqing Fan, Xue Shang, Yan Wang, Yinghua Zhang, Xiuxia Li, Kehu Yang, Haidi Lv, Kangle Guo
{"title":"Lateral-flow device for the diagnosis of invasive aspergillosis: a systematic review and diagnostic meta-analysis.","authors":"Yuqing Fan, Xue Shang, Yan Wang, Yinghua Zhang, Xiuxia Li, Kehu Yang, Haidi Lv, Kangle Guo","doi":"10.1186/s12879-025-10769-x","DOIUrl":"10.1186/s12879-025-10769-x","url":null,"abstract":"<p><strong>Background: </strong>Early diagnosis of invasive aspergillosis (IA) can significantly enhance patient survival rates; however, accurately diagnosing IA remains a formidable challenge. Lateral flow device (LFD), as a non-invasive detection method, have been extensively investigated in numerous clinical studies. The objective of this study was to elucidate the diagnostic accuracy of LFD in detecting IA through a meta-analysis.</p><p><strong>Methods: </strong>The PubMed, Embase, and Web of Science database were searched to obtain clinical studies on the diagnosis of IA by LFD. A random-effects meta-analysis with a bivariate hierarchical model was used, the estimates and 95% confidence intervals (CI) were used to present pooled sensitivity, specificity, and summary receiver operating characteristic curves (SROC).</p><p><strong>Results: </strong>Twenty-five cohort or case-control studies were included. The pooled sensitivity of LFD in the diagnosis of IA was 0.67 (95% CI: 0.57-0.75), specificity was 0.90 (95% CI: 0.85-0.93), diagnostic odds ratio was 15.70 (95% CI: 9.69-25.44), the area under the SROC curve (AUC) was 0.87 (95% CI: 0.82-0.93). Subgroup analysis showed that the sensitivity of bronchoalveolar lavage fluid specimen was higher than serum specimen (0.72, 95% CI: 0.67-0.78 vs. 0.49, 95% CI: 0.41-0.56), bronchoalveolar lavage fluid specimens also have higher diagnostic accuracy (AUC = 0.89).</p><p><strong>Conclusions: </strong>LFD is an effective technique for the detection of IA infection, but attention should be paid to the influence of specimen source on the accuracy of this technique.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"388"},"PeriodicalIF":3.4,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Isolation, genetic, and biological characterization of human adenovirus type 55 positive isolates from Wuhan, China.
IF 3.4 3区 医学
BMC Infectious Diseases Pub Date : 2025-03-20 DOI: 10.1186/s12879-025-10798-6
Jing Xie, Yan Wang, Huan Li, Bingxiu Tan, Zhengying Yu, Lizhong Li, Wei Zhang, Hongbin Song, Leili Jia
{"title":"Correction: Isolation, genetic, and biological characterization of human adenovirus type 55 positive isolates from Wuhan, China.","authors":"Jing Xie, Yan Wang, Huan Li, Bingxiu Tan, Zhengying Yu, Lizhong Li, Wei Zhang, Hongbin Song, Leili Jia","doi":"10.1186/s12879-025-10798-6","DOIUrl":"10.1186/s12879-025-10798-6","url":null,"abstract":"","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"389"},"PeriodicalIF":3.4,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信